Identification and development of therapeutics for COVID-19
(2021) In mSystems 6(6).- Abstract
After emerging in China in late 2019, the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide, and as of mid- 2021, it remains a significant threat globally. Only a few coronaviruses are known to infect humans, and only two cause infections similar in severity to SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a species closely related to SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Unlike the current pandemic, previous epidemics were controlled rapidly through public health measures, but the body of research investigating severe acute respiratory syndrome and Middle East respiratory syndrome has proven... (More)
After emerging in China in late 2019, the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide, and as of mid- 2021, it remains a significant threat globally. Only a few coronaviruses are known to infect humans, and only two cause infections similar in severity to SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a species closely related to SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Unlike the current pandemic, previous epidemics were controlled rapidly through public health measures, but the body of research investigating severe acute respiratory syndrome and Middle East respiratory syndrome has proven valuable for identifying approaches to treating and preventing novel coronavirus disease 2019 (COVID-19). Building on this research, the medical and scientific communities have responded rapidly to the COVID-19 crisis and identified many candidate therapeutics. The approaches used to identify candidates fall into four main categories: adaptation of clinical approaches to diseases with related pathologies, adaptation based on virological properties, adaptation based on host response, and data-driven identification (ID) of candidates based on physical properties or on pharmacological compendia. To date, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA), while most remain under investigation. The scale of the COVID-19 crisis offers a rare opportunity to collect data on the effects of candidate therapeutics. This information provides insight not only into the management of coronavirus diseases but also into the relative success of different approaches to identifying candidate therapeutics against an emerging disease. IMPORTANCE The COVID-19 pandemic is a rapidly evolving crisis. With the worldwide scientific community shifting focus onto the SARS-CoV-2 virus and COVID-19, a large number of possible pharmaceutical approaches for treatment and prevention have been proposed. What was known about each of these potential interventions evolved rapidly throughout 2020 and 2021. This fast-paced area of research provides important insight into how the ongoing pandemic can be managed and also demonstrates the power of interdisciplinary collaboration to rapidly understand a virus and match its characteristics with existing or novel pharmaceuticals. As illustrated by the continued threat of viral epidemics during the current millennium, a rapid and strategic response to emerging viral threats can save lives. In this review, we explore how different modes of identifying candidate therapeutics have borne out during COVID-19.
(Less)
- author
- Rando, Halie M.
; Wellhausen, Nils
; Ghosh, Soumita
; Lee, Alexandra J.
; Dattoli, Anna Ada
; Hu, Fengling
; Byrd, James Brian
; Rafizadeh, Diane N.
; Lordan, Ronan
; Qi, Yanjun
; Sun, Yuchen
; Brueffer, Christian
LU
; Field, Jeffrey M.
; Guebila, Marouen Ben
; Jadavji, Nafisa M.
; Skelly, Ashwin N.
; Ramsundar, Bharath
; Wang, Jinhui
; Goel, Rishi Raj
; Park, Yoson
; Boca, Simina M.
; Gitter, Anthony
and Greene, Casey S.
(Less) - author collaboration
- organization
- publishing date
- 2021-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COVID-19, Review, Therapeutics
- in
- mSystems
- volume
- 6
- issue
- 6
- article number
- e00233-21
- publisher
- American Society for Microbiology
- external identifiers
-
- pmid:34726496
- scopus:85120173390
- ISSN
- 2379-5077
- DOI
- 10.1128/mSystems.00233-21
- language
- English
- LU publication?
- yes
- id
- 00c86cfc-29db-4f26-814b-961c259222fc
- date added to LUP
- 2021-12-15 11:14:17
- date last changed
- 2024-06-29 23:44:56
@article{00c86cfc-29db-4f26-814b-961c259222fc,
abstract = {{<p>After emerging in China in late 2019, the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide, and as of mid- 2021, it remains a significant threat globally. Only a few coronaviruses are known to infect humans, and only two cause infections similar in severity to SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a species closely related to SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Unlike the current pandemic, previous epidemics were controlled rapidly through public health measures, but the body of research investigating severe acute respiratory syndrome and Middle East respiratory syndrome has proven valuable for identifying approaches to treating and preventing novel coronavirus disease 2019 (COVID-19). Building on this research, the medical and scientific communities have responded rapidly to the COVID-19 crisis and identified many candidate therapeutics. The approaches used to identify candidates fall into four main categories: adaptation of clinical approaches to diseases with related pathologies, adaptation based on virological properties, adaptation based on host response, and data-driven identification (ID) of candidates based on physical properties or on pharmacological compendia. To date, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA), while most remain under investigation. The scale of the COVID-19 crisis offers a rare opportunity to collect data on the effects of candidate therapeutics. This information provides insight not only into the management of coronavirus diseases but also into the relative success of different approaches to identifying candidate therapeutics against an emerging disease. IMPORTANCE The COVID-19 pandemic is a rapidly evolving crisis. With the worldwide scientific community shifting focus onto the SARS-CoV-2 virus and COVID-19, a large number of possible pharmaceutical approaches for treatment and prevention have been proposed. What was known about each of these potential interventions evolved rapidly throughout 2020 and 2021. This fast-paced area of research provides important insight into how the ongoing pandemic can be managed and also demonstrates the power of interdisciplinary collaboration to rapidly understand a virus and match its characteristics with existing or novel pharmaceuticals. As illustrated by the continued threat of viral epidemics during the current millennium, a rapid and strategic response to emerging viral threats can save lives. In this review, we explore how different modes of identifying candidate therapeutics have borne out during COVID-19.</p>}},
author = {{Rando, Halie M. and Wellhausen, Nils and Ghosh, Soumita and Lee, Alexandra J. and Dattoli, Anna Ada and Hu, Fengling and Byrd, James Brian and Rafizadeh, Diane N. and Lordan, Ronan and Qi, Yanjun and Sun, Yuchen and Brueffer, Christian and Field, Jeffrey M. and Guebila, Marouen Ben and Jadavji, Nafisa M. and Skelly, Ashwin N. and Ramsundar, Bharath and Wang, Jinhui and Goel, Rishi Raj and Park, Yoson and Boca, Simina M. and Gitter, Anthony and Greene, Casey S.}},
issn = {{2379-5077}},
keywords = {{COVID-19; Review; Therapeutics}},
language = {{eng}},
number = {{6}},
publisher = {{American Society for Microbiology}},
series = {{mSystems}},
title = {{Identification and development of therapeutics for COVID-19}},
url = {{http://dx.doi.org/10.1128/mSystems.00233-21}},
doi = {{10.1128/mSystems.00233-21}},
volume = {{6}},
year = {{2021}},
}